Moderna Sets U.S. Trial for Assessing COVID-19 Vaccine in Teenagers

Moderna Sets U.S. Trial for Assessing COVID-19 Vaccine in Teenagers

Last December 10th, 2020 on the official website of the pharmaceutical company Moderna was announced the plan to begin a phase 2/3 Covid-19 vaccine trial including adolescents between 12-18 years old.

This study is being conducted by Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services.

As reported by Stéphane Bancel, CEO of Moderna “We are pleased to begin this Phase 2/3 study of mRNA-1273 in healthy adolescents in the U.S. Our goal is to generate data during spring 2021 that will support the use of mRNA-1273 in adolescents.”

Further information and details about this study can be found on Moderna website.

 

2021-01-28T10:31:07+00:00 27/01/2021|Categories: News|